ReviewDrug delivery2019
Preparation and drug delivery of dextran-drug complex.
Review in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 100 citations in OpenAlex.
- Intelligent Hydrocolloid-Based Delivery Systems: Innovations in Pharmacy and Cosmetics.Molecules (Basel, Switzerland) · 2026Review
- The Role of Biofunctional Polymers in Polymer-Drug Conjugates: From Passive Carriers to Therapeutically Active Platforms.Pharmaceutics · 2026Review
- Nanotechnology for reproductive healthcare: a comprehensive review.Journal of nanobiotechnology · 2026Review
- Dextran-based stimuli-responsive hydrogels for smart dressings in wound healing.Journal of materials science. Materials in medicine · 2026Review
- Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Natural Polymer-Based Hydrogels for Localized Therapy in Inflammatory Bowel Disease: From Smart Materials to Clinical Translation.Journal of inflammation research · 2026Review
- Targeting the Oral Mucosa: Emerging Drug Delivery Platforms and the Therapeutic Potential of Glycosaminoglycans.Pharmaceutics · 2025Review
- Erythrocyte based achiral micromotors for localized therapeutic delivery.Journal of biological engineering · 2025Article
- Functionalized biomimetic nanoparticles are delivered from the nose to the brain for the synergistic targeted treatment of cerebral ischemia/reperfusion injury.Regenerative biomaterials · 2025Article
- Focused Ultrasound as a Novel Non-Invasive Method for the Delivery of Gold Nanoparticles to Retinal Ganglion Cells.Translational vision science & technology · 2024Article
- Glycan-based scaffolds and nanoparticles as drug delivery system in cancer therapy.Frontiers in immunology · 2024Review
- Natural Polymer-Based Hydrogels: From Polymer to Biomedical Applications.Pharmaceutics · 2023Review
- Preparation of injectable hydrophilic dextran/AgNPs nanocomposite product: White light active biomolecules as an antitumor agent.International journal of biological macromolecules · 2023Article
- New Methacrylated Biopolymer-Based Hydrogels as Localized Drug Delivery Systems in Skin Cancer Therapy.Gels (Basel, Switzerland) · 2023Article
- Dextran Formulations as Effective Delivery Systems of Therapeutic Agents.Molecules (Basel, Switzerland) · 2023Review
- Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease.Journal of nanobiotechnology · 2023Article
- Construction of pH/reduction dual responsive MSN-HAgel containing HApt for tumor targeting carriers.RSC advances · 2022Article
- Craft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity.ACS pharmacology & translational science · 2022Review
- Review
- Water Uptake as a Crucial Factor on the Properties of Cryogels of Gelatine Cross-Linked by Dextran Dialdehyde.Gels (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dextran as a drug carrier for inhibiting cancer cells effectively reduces the toxic and side effects of the drug in the biological body. Targeting improves the concentration of active substance around the target tissue, which reduces damage to other heavy organs and other normal tissues. Dextran will be a potential carrier for the delivery of antitumor drugs in the future, which provides the possibility of slow-release chemotherapy and targeted drug delivery. Herein, the preparation and drug delivery of dextran-drug complex were summarized and discussed in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.